研究概要
BCMA 有潜力成为除 MM 外其他 PCDs 的治疗靶点。
研究思路结论见上方概要
背景
B细胞成熟抗原(BCMA)靶向免疫疗法在多发性骨髓瘤(MM)中已显示出显著的临床疗效。在此,我们评估了MM和其他浆细胞疾病(PCDs)中的BCMA表达,希望为除MM之外的复发/难治性PCDs提供潜在的治疗策略。
方法
2018年1月至2021年8月,本研究共纳入377例PCDs患者,包括334例MM、21例系统性轻链淀粉样变性(AL)、5例POEMS综合征、14例意义未明的单克隆丙种球蛋白病(MGUS)和3例具有肾脏意义的单克隆丙种球蛋白病(MGRS)。通过多参数流式细胞术检测的膜结合BCMA表达由BCMA阳性率和平均荧光强度(MFI)定义。
结果
MM患者的BCMA中位阳性率为88.55%(范围,0.2% - 99.9%),BCMA中位MFI为1281(范围,109 - 48586)。而其他PCDs的BCMA中位阳性率为55.8%(6.2% -98.9%),BCMA中位MFI为553(182- 5930)。在多变量分析中,BCMA表达水平与血红蛋白浓度呈负相关,涉及BCMA阳性率和MFI。
展开英文摘要原文
BACKGROUND
B cell maturation antigen (BCMA) targeted immunotherapies have demonstrated remarkable clinical efficacy in multiple myeloma (MM). Here, we evaluated the BCMA expression in MM and other plasma cell dyscrasias (PCDs), hoping to provide a potential treatment strategy for the relapsed/refractory PCDs besides MM.
METHODS
From January 2018 to August 2021, 377 patients with PCDs were enrolled in this study, including 334 MM, 21 systemic light chain amyloidosis (AL), 5 POEMS syndrome, 14 monoclonal gammopathy of undetermined significance (MGUS), and three monoclonal gammopathy of renal significance (MGRS). The membrane-bound BCMA expression measured by multiparameter flow cytometry was defined by BCMA positivity rate and the mean fluorescence intensity (MFI).
RESULTS
The patients with MM had a median BCMA positive rate of 88.55% (range, 0.2% - 99.9%) and median BCMA MFI of 1281 (range, 109 - 48586). While the median BCMA positive rate in other PCDs was 55.8% (6.2% -98.9%), and the median BCMA MFI was 553 (182- 5930). BCMA expression level was negatively associated with hemoglobin concentration in multivariate analysis in terms of BCMA positive rate and MFI.
CONCLUSIONS
In conclusion, BCMA has the potential to be a therapeutic target for other PCDs besides MM.
论文信息
- 作者
- Xu Y、Mao X、Que Y、Xu M、Li C、Almeida VDF、Wang D、Li C
- 第一作者单位
- Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei, 430030, P. R. China.China
- 通讯作者单位
- Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei, 430030, P. R. China. cunrui5650@hust.edu.cn.China
- 期刊
- BMC cancer2023 Feb 7